CAR T-Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

CAR T-Cell Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Fairfield Market Research, a leading market research firm, has released a comprehensive analysis of the CAR T-cell therapy market, forecasting continued growth in the sector. According to the latest industry study, the global CAR T-cell therapy market valued is projected to reach US$ 2.8 billion by 2031.

Rising Demand for CAR T-Cell Therapy Fuelled by Advancements in Cancer Treatment

CAR T-cell therapy, a revolutionary approach in cancer treatment, has garnered significant attention and investment in recent years. This therapy involves extracting T-cells from a patient's blood, modifying them in a lab by adding a gene for a man-made receptor called a chimeric antigen receptor (CAR), and reintroducing these engineered cells back into the patient's body. By enhancing the recognition of specific cancer cell antigens, CAR T-cells offer a promising avenue for targeted cancer therapy.

The persistent increase in the prevalence of cancer globally has been a key driver for the growing demand for CAR T-cell therapy. Moreover, advancements in research and development in the life sciences and biotechnology sectors have paved the way for the exploration of artificial T-cell receptors and chimeric immunoreceptors, further expanding the therapeutic potential of CAR T-cell therapy across various types of cancer.

Key Opportunities and Market Insights

Market players involved in CAR T-cell therapy are presented with several opportunities for growth and innovation. The emphasis on research and development for treating various types of cancers, including lung cancer, colorectal cancer, multiple myeloma cancer, and prostate cancer, is expected to create significant avenues for expansion in the CAR T-cell therapy market. Additionally, favorable government policies and funding initiatives are likely to further propel the demand for CAR T-cell therapy in the foreseeable future.

Regional Outlook: U.S. and Germany Lead the Way

The United States remains a pivotal market for CAR T-cell therapy, with over 98% value share in the North American market. The increasing focus of life sciences companies on the development and commercial manufacturing of CAR T-cells, coupled with improvements in quality control systems, continues to drive demand in the U.S. market.

Germany emerges as a lucrative market for CAR T-cell therapy in Europe, expected to account for nearly 27% of the market share by 2031. Factors such as the aging population and favorable regulatory landscape contribute to the growing demand for CAR T-cell therapy in Germany.

Competitive Analysis

Key companies functioning in the market including:
• Novartis AG
• Gilead Sciences Inc.
• Celgene Corporation
• bluebird bio, Inc.

Car T-Cell Therapy Industry Research by Category

Product
• Yescarta (axicabtagene ciloleucel)
• Kymriah (tisagenlecleucel)
• JCAR017 (lisocabtagene maraleucel)
• bb2121

Indication
• Relapsed Large B-cell Lymphoma
• Acute Lymphoblastic Leukemia (ALL)
• Multiple Myeloma

End User
• Car T-Cell Therapy at Hospitals
• Car T-Cell Therapy at Cancer Treatment Centers

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.